
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in **RENHENG Enterprise Holdings Limited**, you should at once hand this circular and the accompanying proxy form to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



RENHENG ENTERPRISE HOLDINGS LIMITED **仁恒實業控股有限公司**

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 3628)

PROPOSED GRANT OF GENERAL MANDATES TO ISSUE NEW SHARES AND REPURCHASE OF SHARES; PROPOSED RE-ELECTION OF DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING

The notice convening the annual general meeting of the Company to be held at Room 3805, 38/F, Far East Finance Centre, 16 Harcourt Road, Admiralty, Hong Kong, on 25 June 2025 at 11:00 a.m. is set out on pages 17 to 20 of this circular.

A proxy form for use at the annual general meeting is enclosed with this circular. Whether or not you are able to attend the annual general meeting, you are requested to complete the proxy form and return the same to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong in accordance with the instructions printed thereon as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the annual general meeting or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting in person at the annual general meeting or any adjourned meeting (as the case may be) if you so wish.

CONTENTS

	<i>Page(s)</i>
Definitions	1
Letter from the Board	
Introduction	3
Proposed General Mandate and Repurchase Mandate	4
Proposed Re-election of Directors	5
Notice of Annual General Meeting	6
Form of Proxy	6
Voting by Poll	6
Responsibility Statement	6
Closure of Register of Members.....	7
Recommendations	7
Appendix I – Explanatory Statement	8
Appendix II – Details of Directors Proposed for Re-election	12
Notice of Annual General Meeting	17

DEFINITIONS

In this circular and the appendices, unless the context requires otherwise, the following expressions have the following meanings:

“Annual General Meeting”	the annual general meeting of the Company to be held at Room 3805, 38/F, Far East Finance Centre, 16 Harcourt Road, Admiralty, Hong Kong, on 25 June 2025 at 11:00 a.m., or any adjournment thereof
“Articles of Association”	the articles of association of the Company, as amended from time to time, and “Article” shall mean an article thereof
“Board”	the board of Directors
“Company”	RENHENG Enterprise Holdings Limited, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Stock Exchange (stock code: 3628)
“Director(s)”	the directors of the Company
“General Mandate”	the general mandate proposed to be granted to the Directors at the AGM to exercise all the powers of the Company to allot, issue and deal with new Shares including any sale or transfer of treasury shares not exceeding 20% of the issued share capital of the Company (excluding treasury shares) as at the date of passing of the relevant resolution by the Shareholders
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Latest Practicable Date”	17 April 2025, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended from time to time
“Notice”	the notice of the AGM set out on pages 17 to 20 of this circular

DEFINITIONS

“Repurchase Mandate”	the repurchase mandate proposed to be granted to the Directors at the AGM to exercise the power of the Company to repurchase up to a maximum of 10% of the issued share capital of the Company (excluding treasury shares) as at the date of passing of the relevant resolution by the Shareholders
“SFC”	the Securities and Futures Commission of Hong Kong
“Share(s)”	ordinary share(s) of HK\$0.0025 each in the share capital of the Company
“Shareholder(s)”	registered holder(s) of the Share(s) in issue
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers and Share Buy-backs
“treasury shares”	has the meaning ascribed to this term in the Listing Rules
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“%”	per cent.

LETTER FROM THE BOARD



RENHENG ENTERPRISE HOLDINGS LIMITED

仁恒實業控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 3628)

Directors:

Executive Directors

Ms. Liu Li

(Chairman & Chief Executive Officer)

Ms. Lew Lai Kuen

Mr. Wen Yuan

Independent Non-Executive Directors

Dr. Lam, Lee G.

Mr. Lam Chi Wing

Mr. Wu Wei

Registered Office:

P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands

**Head Office and Principal Place
of Business in Hong Kong:**

Room 3805, 38/F
Far East Finance Centre
16 Harcourt Road
Admiralty Hong Kong

29 April 2025

Dear Shareholder(s),

**PROPOSED GRANT OF GENERAL MANDATES
TO ISSUE NEW SHARES AND REPURCHASE OF SHARES;
PROPOSED RE-ELECTION OF DIRECTORS;
AND
NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information in respect of the following resolutions to be proposed at the AGM:

- (a) granting of the General Mandate and the Repurchase Mandate;
- (b) re-election of the retiring Directors;
- (c) approving other ordinary businesses to be considered at the AGM, including, among others, the approval and adoption of the audited financial statements and reports of the Directors and auditors of the Company for the year ended 31

LETTER FROM THE BOARD

December 2024, the fixing of Directors' remuneration, the appointment of the incumbent auditors of the Company and the authorization to the Board to fix their remuneration; and

- (d) to serve the notice of the AGM.

PROPOSED GENERAL MANDATE AND REPURCHASE MANDATE

At the AGM, the Directors propose to seek the approval of the Shareholders to grant to the Directors the General Mandate and the Repurchase Mandate.

General Mandate

At the annual general meeting of the Company held on 19 June 2024, the Directors were granted a general mandate to allot, issue and deal with ordinary shares of HK\$0.0025 each in the capital of the Company on the Stock Exchange. No shares have been issued under the mandate and the mandate will expire at the conclusion of the AGM.

It will be proposed at the AGM an ordinary resolution, which is set out in resolution no. 5(1) of the Notice granting the Directors a general mandate to allot, issue, and deal with unissued Shares or underlying Shares (other than by way of rights or pursuant to a share option scheme for employees of the Company or Directors and/or any of its subsidiaries or pursuant to any scrip dividend scheme or similar arrangements providing for the allotment and issue of Shares in lieu of whole or part of the dividend on Shares in accordance with the Articles of Association) or make or grant offers, agreements, options and warrants which might require the exercise of such power, of an aggregate amount of up to 20% of the issued Shares (excluding treasury shares) as at the date of passing the resolution approving the General Mandate. The Directors wish to state that they have no immediate plan to issue Shares pursuant thereto.

In addition, the Board also proposed to extend the General Mandate authorizing the Directors to allot, issue and deal with Shares to the extent of the Shares repurchased pursuant to the Repurchase Mandate.

The Company has in issue an aggregate of 804,000,000 Shares (excluding treasury shares) as at the Latest Practicable Date. Subject to the passing of the resolutions for the approval of the General Mandate and in accordance with the terms therein, the Company would be allowed to allot, issue and deal with a maximum of 160,800,000 Shares (including any sale or transfer of treasury shares) on the basis that no further Shares will be issued or repurchased by the Company prior to the AGM.

Repurchase Mandate

At the annual general meeting of the Company held on 19 June 2024, the Directors were granted a general mandate to repurchase Shares on the Stock Exchange of an aggregate amount of up to 10% of the issued Shares (excluding treasury shares). No shares have been repurchased under the mandate and the mandate will expire at the conclusion of the AGM.

LETTER FROM THE BOARD

At the AGM, an ordinary resolution, which is set out in resolution no. 5(2) of the Notice, will also be proposed to grant to the Directors to exercise all powers of the Company to repurchase Shares on the Stock Exchange of an aggregate amount of up to 10% of the issued Shares (excluding treasury shares) as at the date of passing the resolution approving the Repurchase Mandate.

Subject to the passing of the resolution for the approval of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased prior to the AGM, the Company would be allowed under the Repurchase Mandate to repurchase a maximum of 80,400,000 Shares.

An explanatory statement containing all information in relation to the Repurchase Mandate as required under Rule 10.06(1) of the Listing Rules is set out in **Appendix I** to this circular.

The General Mandate (including the extended General Mandate) and the Repurchase Mandate shall continue to be in force until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws of the Cayman Islands to be held; or (iii) the revocation or variation of the General Mandate (including the extended General Mandate) or the Repurchase Mandate (as the case may be) by ordinary resolution of the Shareholders in general meeting.

PROPOSED RE-ELECTION OF DIRECTORS

The Board currently comprises three executive Directors, namely Ms. Liu Li (“**Ms. Liu**”), Ms. Lew Lai Kuen (“**Ms. Lew**”) and Mr. Wen Yuan (“**Mr. Wen**”) and three independent non-executive Directors, namely Dr. Lam, Lee G. (“**Dr. Lam**”), Mr. Lam Chi Wing (“**Mr. Lam**”) and Mr. Wu Wei (“**Mr. Wu**”).

Pursuant to the Listing Rules and Article 16.2, all directors appointed to fill a casual vacancy or as an addition to the Board should be subject to election by shareholders at the first general meeting after appointment. Ms. Lew and Mr. Wen have been appointed to fill a causal vacancy or as an addition to the Board during the year.

In accordance with Article 16.18, at every annual general meeting of the Company one-third of the Directors for the time being (or, if their number is not three or a multiple of three, then the number nearest to, but not less than, one-third) shall retire from office by rotation provided that every Director (including those appointed for a specific term) shall be subject to retirement by rotation at least once every three years.

Accordingly, Mr. Wu and Dr. Lam being the longest-serving Directors, and Ms. Lew and Mr. Wen shall retire at the AGM and being eligible, offer himself/herself for re-election.

Details of Directors proposed for re-election are set out in **Appendix II** to this circular.

LETTER FROM THE BOARD

NOTICE OF ANNUAL GENERAL MEETING

The Notice is set out on pages 17 to 20 of this circular. Resolutions to be proposed at the AGM include, *inter alia*:

- (i) the granting of the General Mandate (including the extended General Mandate) and the Repurchase Mandate;
- (ii) approving the proposed re-election of the retiring Director, namely Ms. Lew and Mr. Wen as an executive Director and Mr. Wu and Dr. Lam as an independent non-executive Director;
- (iii) approving other ordinary businesses to be considered, including, among others, the approval of the audited financial statements and reports of the Directors and auditors of the Company, the fixing of Directors' remuneration, the appointment of the incumbent auditors of the Company and the authorization to the Board to fix their remuneration.

FORM OF PROXY

A proxy form for use at the AGM is enclosed herein. Whether or not you intend to attend the AGM, you are requested to complete and return the accompanying proxy form in accordance with the instructions printed thereon and deposit the same at the Hong Kong branch share register of the Company, Tricor Investor Services Limited at 17/F Far East Finance Centre, 16 Harcourt Road, Hong Kong, as soon as possible and in any event not less than 48 hours before the time appointed for the holding of the AGM or any adjournment thereof. Completion and return of the proxy form will not preclude you from attending and voting in person at the AGM or any adjournment thereof if you so wish.

VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of Shareholders at a general meeting must be taken by poll. At the AGM, the chairman of the meeting will exercise his power under the Articles of Association to put all the resolutions set out in the Notice to the vote by way of poll. An announcement of the results of the poll will be made by the Company thereafter.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

LETTER FROM THE BOARD

CLOSURE OF REGISTER OF MEMBERS

For determination of the entitlement to attend and vote at the Annual General Meeting, the transfer books and register of members will be closed from Friday, 20 June 2025 to Wednesday, 25 June 2025 (both days inclusive) during which no transfer of Shares will be effected. In order to qualify for attending and voting at the Annual General Meeting, all transfers accompanied by the relevant share certificates must be lodged with the Company's Hong Kong branch share registrar and transfer office, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on Thursday, 19 June 2025.

RECOMMENDATIONS

The Directors believe that the proposed General Mandate (including the extended General Mandate) and the Repurchase Mandate and the proposed re-election of retiring Directors are in the best interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend you to vote in favour of the resolutions to be proposed at the AGM.

Yours faithfully,
By order of the Board
RENHENG Enterprise Holdings Limited
Liu Li
Chairman & Chief Executive Officer

This Appendix I serves as an explanatory statement given to all Shareholders relating to a resolution to be proposed at the AGM authorizing the proposed Repurchase Mandate. This explanatory statement contains all information pursuant to Rule 10.06(1) of the Listing Rules and other relevant provisions of the Listing Rules which is set out as follows:

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 804,000,000 Shares (excluding treasury shares).

Subject to the passing of the resolution for the approval of the Repurchase Mandate and on the basis that no further Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to purchase a maximum of 80,400,000 Shares, representing 10% of the issued share capital of the Company (excluding treasury shares) as at the date of passing of the resolution, until the earliest of (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of Association or any applicable laws of the Cayman Islands to be held; or (iii) the revocation or variation of the Repurchase Mandate by an ordinary resolution of the Shareholders in general meeting.

2. REASONS FOR PROPOSED REPURCHASES OF SHARES

The Directors believe that it is in the best interests of the Company and the Shareholders to seek a general authority from the Shareholders to enable the Directors to repurchase Shares on the Stock Exchange. Such repurchases may, depending on market conditions and funding arrangements at the time, lead to an enhancement of the net assets of the Company and/or its earnings per share and will only be made when the Directors believe that such repurchases will benefit the Company and its Shareholders as a whole.

3. SOURCE OF FUNDS

In repurchasing Shares, the Company may only apply funds legally available for such purpose in accordance with the Articles of Association, the applicable laws of the Cayman Islands and the Listing Rules. It is envisaged that the funds required for any repurchase may also be derived from the Company's available cash flow or internal resources.

4. EFFECT OF EXERCISING THE REPURCHASE MANDATE

Taking into account the current capital position of the Company, the Directors consider that, the exercise in full of the Repurchase Mandate to repurchase Shares might have an adverse impact on the working capital or gearing position of the Company (as compared with the positions disclosed in the audited financial statements contained in the annual report of the Company for the year ended 31 December 2024). However, the Directors do not propose to exercise the Repurchase Mandate to such an extent as would, in the circumstances, have an adverse effect on the working capital or on the gearing levels which, in the opinion of the Directors, are from time to time appropriate for the Company.

5. DISCLOSURE OF INTERESTS

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their respective associates (as defined in the Listing Rules) has any present intention to sell any Shares to the Company under the Repurchase Mandate if it is approved by the Shareholders at the AGM.

6. DIRECTORS' UNDERTAKING

The Directors have undertaken to the Stock Exchange to exercise the power of the Company to make purchases pursuant to the Repurchase Mandate in accordance with the Articles of Association, the Listing Rules and the applicable laws of the Cayman Islands.

7. TAKEOVERS CODE

If, as a result of a repurchase of Shares pursuant to the Repurchase Mandate, a Shareholder's proportional interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purposes of Rule 32 of the Takeovers Code. As a result, a Shareholder or group of Shareholders acting in concert (within that term's meaning under the Takeovers Code), depending on the level of increase in the shareholders' interests, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, to the best knowledge and belief of the Directors, the following persons were directly or indirectly interested in 5% or more of the nominal value of the issued ordinary Shares that carry a right to vote in all circumstances at general meetings of the Company:

Name	Nature of interest	Number of Shares held/ interested	Approximate percentage (%) of shareholding interests
(1) LinkBest Capital Group Limited (“LinkBest”) (Note 1)	Beneficial interest	360,000,000	44.8%
(2) Open Venture Global Limited (“Open Venture”) (Note 1)	Beneficial interest	240,000,000	29.8%
(3) Liu Li (“Ms. Liu”)	Interest of controlled corporations	600,000,000	74.6%

Note 1: LinkBest and Open Venture are wholly owned by Ms. Liu.

In the event that Repurchase Mandate is exercised in full, the aforesaid interest of (1) LinkBest; (2) Open Venture; and (3) Ms. Liu in the issued share capital of the Company as at the Latest Practicable Date would be proportionally increased to (1) approximately 49.75%; (2) approximately 33.17%; and (3) approximately 82.92% respectively.

On the basis of the shareholding held by each substantial Shareholder as set out above, an exercise of the Repurchase Mandate in full may give rise to an obligation for LinkBest and Open Venture to make a mandatory offer under Rules 26 and 32 of the Takeovers Code. However, the Company and the Directors have no current intention to exercise the Repurchase Mandate to such extent as would give rise to the obligation.

Save as disclosed above, the Directors are not aware of any other consequences which would arise under the Takeovers Code as a consequence of any repurchase pursuant to the Repurchase Mandate.

The Directors are also aware that the Listing Rules prohibit a company from making repurchase on the Stock Exchange if the result of the repurchase would be that less than 25% (such other prescribed minimum percentage as determined by the Stock Exchange) of the issued share capital would be in the hands of the public. The Directors have no present intention to exercise the Repurchase Mandate to such an extent that would result in the Company failing to comply with the public float requirements under Rule 8.08 of the Listing Rules.

8. REPURCHASES OF SHARES BY THE COMPANY

No purchase of Shares (whether on the Stock Exchange or otherwise) has been made by the Company during the six months preceding the Latest Practicable Date.

9. CONNECTED PERSON

No connected person (as defined in the Listing Rules) has notified the Company that he has a present intention to sell Shares to the Company or has undertaken not to do so in the event that the Repurchase Mandate is approved by the Shareholders.

10. SHARES PRICES

The highest and lowest prices at which the Shares were traded on the Stock Exchange during each of the previous twelve months were as follows:

Month	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2024		
March	0.465	0.230
April	0.148	0.130
May	0.195	0.148
June	0.202	0.150
July	0.185	0.179
August	0.185	0.185
September	0.200	0.160
October	0.190	0.180
November	0.195	0.101
December	0.154	0.112
2025		
January	0.128	0.110
February	0.125	0.115
March	0.118	0.102
April (up to the Latest Practicable Date)	0.110	0.109

'This appendix provides you with the biographical details of the Directors who will retire from their offices at the AGM and being, eligible, will offer themselves for re-election, at the AGM in accordance with the Articles of Association.

PROPOSED RE-ELECTION OF DIRECTORS

Ms. Lew Lai Kuen

Ms. Lew, aged 61, is an executive director of the Company and is responsible for overall business planning, strategic development, human resources and administrative functions of the Group. Ms. Lew was appointed as an executive director in July 2024.

Ms. Lew obtained a professional diploma in logistics management from International Transport & Logistics Association in collaboration with International City University of America in June 2005. Ms. Lew joined Far East Polyfoam Ltd. from October 1982 to July 1985, where she served as a clerk of the company. From January 1986 to April 2003, Ms. Lew joined Oceancrete Limited and served as a marketing officer to assist the marketing manager for overseas and local sales. Prior to joining our Group, Ms. Lew joined Yanlord Paper Limited to serve as a marketing manager responsible for managing the department of marketing and customer services and providing professional customer support to the customers since August 2003.

Ms. Lew has entered into a letter of appointment (the “**Letter of Appointment**”) with the Company for her role as an executive director of the Company with no specific length of service and her term of service shall continue unless and until terminated by either party by giving to the other three months’ prior notice or payment in lieu of notice. Pursuant to the Letter of Appointment, Ms. Lew will hold office until the next annual general meeting of the Company and is eligible for re-election at such meeting, and she will be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and the articles of association of the Company. Ms. Lew is entitled to receive a director’s fee of HK\$12,000 per annum, other emoluments of HK\$338,000 per annum, and a discretionary bonus or other benefits which are based on the performance of the Group and of Ms. Lew. The emolument of Ms. Lew is determined by the Board on the recommendation of the remuneration committee of the Company with reference to her duties, responsibilities, experience and the prevailing market conditions.

As at the Latest Practicable Date, Ms. Lew does not hold any interest or short position in the Shares, underlying shares or debentures of the Company or its associate corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Wen Yuan

Mr. Wen, aged 57, is an executive director of the Company and is responsible for overall business planning, strategic development, human resources and administrative functions of the Group. Mr. Wen was appointed as an executive director in December 2024.

Mr. Wen obtained a bachelor's degree in Chinese Language and Literature Education from Northeast Normal University in China in June 1996. Mr. Wen was awarded as Senior Economist in Economic Management from Jilin Provincial Personnel Department of China in January 2008. Mr. Wen joined Jilin Province Baishan City Fusong County Municipal Engineering Company (吉林省白山市撫松縣市政工程公司) from March 1990 to March 1992 and served as the office director. From August 1994 to May 2014, Mr. Wen joined Jilin Province Baishan City Fusong First Pharmaceutical Factory (吉林白山撫松第一製藥廠) and served as general manager to oversee the general affairs of the factory. From May 2014 to December 2020, Mr. Wen joined Sinopharm Pharmaceutical Co., Ltd. (國藥藥材股份有限公司) and served as general manager and acted as the chairman to oversee the general affairs of the company. Prior to joining our Group, Mr. Wen joined China Pharmaceutical Culture Society (中國藥文化研究會) to serve as vice-chairman and was responsible for organizing academic exchange and holding forum lectures since December 2020. Mr. Wen served as vice-president of China Russia Regional Cooperation and Development Investment Fund Management Co., Ltd. (中俄地區合作發展投資基金管理有限責任公司) and was responsible for researching medical equipment and devices and pharmaceutical and energy since December 2023.

Mr. Wen has entered into a letter (the "**Letter of Appointment**") with the Company for his role as an executive Director with no specific length of service and his term of service shall continue unless and until terminated by either party by giving to the other three months' prior notice or payment in lieu of notice. Pursuant to the Letter of Appointment, Mr. Wen will hold office until the next annual general meeting of the Company and is eligible for re-election at such meeting, and he will be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company and in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the articles of association of the Company. Mr. Wen is entitled to a director's fee payable of HK\$120,000 per annum, and a discretionary bonus or other benefits which are based on the performance of the Group and of Mr. Wen. The emolument of Mr. Wen is determined by the remuneration committee of the Company, with delegated responsibility pursuant to the authority given by the shareholders of the Company (the "**Shareholders**") at the Company's last annual general meeting and with reference to his duties and responsibilities, experience and the prevailing market conditions.

As at the Latest Practicable Date, Mr. Wen does not hold any interest or short position in the Shares, underlying shares or debentures of the Company or its associate corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Dr. Lam, Lee G.

Dr. Lam Lee G. (“**Dr. Lam**”), aged 65, joined the Group in 2022. He is chairman of the Audit Committee and is a member of each of the Remuneration Committee and the Nomination Committee. Dr. Lam has extensive international experience in corporate management, strategy consulting, corporate governance, direct investment, investment banking and asset management.

Dr. Lam holds a BSc in Sciences and Mathematics, an MSc in Systems Science and an MBA from the University of Ottawa in Canada, a post-graduate Diploma in Public Administration from Carleton University in Canada, an LLB (Hons) in law and an LLM (Legal Practice) from Manchester Metropolitan University in the UK, an LLM (Corporate Law) from the University of Wolverhampton in the UK, a PCLL in law from the City University of Hong Kong, a Certificate of Professional Accountancy from the Chinese University of Hong Kong SCS, an MPA and a PhD from the University of Hong Kong. Dr. Lam was a practicing Solicitor of the High Court of Hong Kong (and formerly a member of the Hong Kong Bar). He is an Accredited Mediator of the Centre for Effective Dispute Resolution, a Fellow of Certified Management Accountants (CMA) Australia, the Hong Kong Institute of Arbitrators and the Hong Kong Institute of Directors, an international affiliate of the Hong Kong Institute of Certified Public Accountants (HKICPA), an Honorary Fellow of Certified Public Accountants (CPA) Australia, the Hong Kong Institute of Facility Management and the University of Hong Kong School of Professional and Continuing Education, and a Distinguished Fellow of the Hong Kong Innovative Technology Development Association.

Also active in community service and international exchange and cooperation, Dr. Lam is Chairman of the Innovation and Technology Committee of the Belt and Road General Chamber of Commerce, Advisor to Our Hong Kong Foundation, Advisor to Hong Kong Investor Relations Association, Consultant to Hong Kong Legal Exchange Foundation, Senior Advisor to the Australian Chamber of Commerce in Hong Kong and Macau, Senior Advisor to Yesports Master Club, Honorary President of Internet Professional Association, Founding Advisor to Hong Kong Digital Asset Society, Honorary Advisor to Hong Kong PropTech Association, Chair of the United Nations ESCAP Sustainable Business Network Finance Task Force, and a member of the Board of Directors and Chairman of the Permanent Commission on Economic and Financial Issues of the World Union of Small and Medium Enterprises.

Dr. Lam is an independent non-executive director of each of RENHENG Enterprise Holdings Limited (Stock Code: 3628) and Sinohope Technology Holdings Limited (Stock Code: 1611), and a non-executive director of Mingfa Group (International) Company Limited (Stock Code: 846; he was re-designated from independent non-executive director on 23 April 2020), the shares of all of which are listed on the Stock Exchange. He is also an independent non-executive director of AustChina Holdings Limited (Stock Code: AUH) whose shares are listed on the Australian Securities Exchange.

In the past three years, Dr. Lam was an executive director of USPACE Technology Group Limited (Stock Code: 1725, fka Hong Kong Aerospace Technology Group Limited; he was re-designated from non-executive director on 3 January 2022) up to May 2024, a non-executive director of Sunwah Kingsway Capital Holdings Limited (Stock Code: 188), China Hong Kong Power Smart Energy Group Limited (fka China LNG Group Limited, Stock Code: 931) both up to February 2024 and National Arts Group Holdings Limited (Stock Code: 8228) up to July 2022. He was also an independent non-executive director of Mei Ah Entertainment Group Limited (Stock Code: 391) up to 30 December 2024, Hang Pin Living Technology Company Limited (Stock Code: 1682) up to October 2024, Greenland Hong Kong Holdings Limited (Stock Code: 337) up to May 2024, Kidsland International Holdings Limited (Stock Code: 2122) up to April 2024, Huarong International Financial Holdings Limited (Stock Code: 993) and CSI Properties Limited (Stock Code: 497) both up to March 2024, Vongroup Limited (Stock Code: 318), MOS House Group Limited (Stock Code: 1653) and Elife Holdings Limited (Stock Code: 223) up to February 2024 and Haitong Securities Company Limited (Stock Code: 6837; also listed on the Shanghai Stock Exchange Stock Code: 600837) up to October 2023, the shares of all of which are listed on the Stock Exchange. He was a non-executive director of Jade Road Investments Limited (Stock Code: JADE, listed on the London Securities Exchange) up to July 2024, an independent non-executive director of each of TMC Life Sciences Berhad (Stock Code: 0101, listed on the Bursa Malaysia) up to May 2023, Asia-Pacific Strategic Investments Limited (Stock Code: 5RA) up to October 2024, Thomson Medical Group Limited (Stock Code: A50) and Alset International Limited (Stock Code: 40V; re-designated from non-executive director on 2 July 2020), both up to November 2023, and Beverly JCG Ltd. (Stock Code: VFP) up to April 2023 (the shares of all of which are listed on the Singapore Exchange).

Dr. Lam had entered into a letter of appointment with the Company as an independent non-executive Director for a term of 3 years commencing on 30 June 2022. Dr. Lam will be subject to the retirement by rotation and re-election provisions in the Articles of Association, and the appointment shall continue unless terminated by not less than one month's notice in writing served by either party on the other. Dr. Lam is entitled to receive an annual director's fee of HK\$120,000, which is determined based on the estimated time to be spent by him on the Company's matters. Save as disclosed, he is not entitled to any other emoluments for holding his office as an independent non-executive Director.

As at the Latest Practicable Date, Dr. Lam does not hold any interest or short position in the Shares, underlying shares or debentures of the Company or its associate corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Mr. Wu Wei

Mr. Wu, aged 51, is an independent non-executive Director and the chairman of the nomination committee, and a member of the audit committee and the remuneration committee of the Company. He holds a Bachelor's Degree of Arts from Columbia University. He has over 23 years' experience in enterprise investment and investment banking. He is a senior partner of Maison Capital Co. Ltd., a private equity fund manager. Mr. Wu previously served as managing director of CITIC Securities International Company Limited where he was responsible for its private equity business. He also served in Deutsche Bank AG, Henderson Global Investors (Hong Kong) Limited and Lehman Brothers Asia Limited. He was an independent non-executive Director of AVIC International Holdings Limited whose shares are listed on the Stock Exchange till 17 April 2020. He was appointed as an independent non-executive Director with effect from 31 October 2014.

Mr. Wu has entered into a service contract with the Company as an executive Director for a term of three years commencing from 20 October 2020 and has renewed a service agreement with the Company as a director for 3 years with effect from October 2023. Mr. Wu will be subject to the retirement by rotation and re-election provisions in the Articles of Association, and the appointment shall continue unless terminated by one months' notice in writing served by either party on the other. Mr. Wu is entitled to receive an annual director's fee of HK\$120,000, which is determined based on the estimated time to be spent by him on the Company's matters. Save as disclosed, he is not entitled to any other emoluments for holding his office as an independent non-executive Director.

As at the Latest Practicable Date, Mr. Wu does not hold any interest or short position in the Shares, underlying shares or debentures of the Company or its associate corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed, each of Ms. Lew, Mr. Wen, Mr. Wu and Dr. Lam does not hold any other position with the Company or other members of the Group. In addition, each of Ms. Lew, Mr. Wen, Mr. Wu and Dr. Lam does not have any other major appointments or professional qualifications and has not held any position in other public companies listed on the Stock Exchange or any other securities market in the last three years. In addition, each of Ms. Lew, Mr. Wen, Mr. Wu and Dr. Lam does not have any relationship with any other directors, senior management or substantial or controlling shareholders of the Company or any of their associates (as defined in the Listing Rules).

Save as disclosed above and to the best of the Board's knowledge, information and belief, having made all reasonable enquiries, there is no other information relating to the proposed re-election of the retiring Directors that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules nor the Board is aware of any other matters that need to be brought to the attention of the Shareholders in respect of the above proposed appointments.

NOTICE OF ANNUAL GENERAL MEETING



RENHENG ENTERPRISE HOLDINGS LIMITED

仁恒實業控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 3628)

NOTICE IS HEREBY GIVEN that an annual general meeting of RENHENG Enterprise Holdings Limited (the “**Company**”) will be held at Room 3805, 38/F, Far East Finance Centre, 16 Harcourt Road, Admiralty, Hong Kong, on 25 June 2025 at 11:00 a.m. for the purpose of considering the following resolutions:

AS ORDINARY BUSINESS

A. To consider and, if thought fit, passing with or without amendments, the following resolutions as ordinary resolutions THAT:

1. To receive and consider the audited financial statements and the reports of the directors of the Company (the “**Directors**”) and auditors of the Company for the year ended 31 December 2024.
2. (a) To re-elect Ms. Lew Lai Kuen as an executive Director.
(b) To re-elect Mr. Wen Yuan as an executive Director.
(c) To re-elect Mr. Wu Wei as an independent non-executive Director.
(d) To re-elect Dr. Lam Lee G. as an independent non-executive Director.
3. To authorize the board of Directors (the “**Board**”) to fix the Directors’ remuneration.
4. To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorize the Board to fix their remuneration.

AS SPECIAL BUSINESS

B. To consider and, if thought fit, passing with or without amendments, the following resolutions as ordinary resolutions:

“**THAT:**

5(1) (a) subject to paragraph (c) below, and pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) the exercise by the Directors during the

NOTICE OF ANNUAL GENERAL MEETING

Relevant Period (as hereinafter defined) of all the powers of the Company to allot, issue and deal with additional ordinary shares of HK\$0.0025 each in the capital of the Company (the “Shares”) (including any sale and transfer of treasury shares) and to make or grant whether conditionally or unconditionally, offers, agreements and options (including warrants, bonds and debentures convertible into Shares) which would or might require the exercise of such power be and is hereby generally and unconditionally approved;

- (b) the Directors be and are hereby authorized during the Relevant Period to make or grant offers, agreements and options (including warrants, bonds and debentures convertible into Shares) which would or might require the exercise of such powers during or after the end of the Relevant Period;
- (c) the aggregate nominal amount of Shares allotted, issued and dealt with or agreed conditionally or unconditionally to be allotted, issued and dealt with (whether pursuant to an option or otherwise) by the Directors pursuant to the approval in paragraph 5(1)(a) and (b), **otherwise than pursuant to** (i) a Rights Issue (as hereinafter defined), (ii) the exercise of any rights of subscription or conversion under the terms of any warrants issued by the Company or any securities which are otherwise convertible into Shares, (iii) the exercise of any options granted under a share option scheme or similar arrangement of the Company for the time being adopted by the Company, or (iv) an issue of Shares in lieu of the whole or part of a dividend on Shares or any script dividend scheme or similar arrangement providing for the allotment and issue of Shares in accordance with the memorandum and articles of association of the Company in force from time to time, **shall not exceed the aggregate of:**
 - (i) twenty per cent. (20%) of the aggregate nominal amount of the share capital of the Company in issue (excluding treasury shares) as at the date of passing this resolution; and
 - (ii) subject to the passing of the resolution no. 5(2), the nominal amount of any share capital repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10 per cent. (10%) of the aggregate nominal amount of the share capital of the Company in issue (excluding treasury shares) as at the date of passing of resolution no. 5(2)),
- and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and
- (d) for the purpose of resolution nos. 5(1) and 5(2):

NOTICE OF ANNUAL GENERAL MEETING

“Relevant Period” means the period from the time of the passing this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company, the Companies Law of the Cayman Islands or any applicable laws of Cayman Islands to be held; or
- (iii) the revocation or variation of the authority given under this resolution by an ordinary resolution of the shareholders of the Company in general meeting.

“Rights Issue” means an offer of Shares, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to the holders of Shares and/or warrants on the respective registers of the Company on a fixed record date in proportion to their then holdings of such Shares and/or warrants (subject to such exclusion or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, any recognized regulatory body or any stock exchange applicable to the Company).

5(2) (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as hereinabove defined) of all the powers of the Company to repurchase the Shares on the Stock Exchange or any other stock exchange on which the Shares may be listed and recognized by the Securities and Futures Commission of Hong Kong and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the Securities and Futures Commission of Hong Kong, the Stock Exchange or of any other stock exchange as amended from time to time, the Companies Law of the Cayman Islands and all other applicable laws in this regard, be and the same is hereby generally and unconditionally approved; and

(b) the aggregate nominal amount of the Shares which the Company is authorized to repurchase pursuant to the approval in paragraph 5(2)(a) of this resolution during the Relevant Period shall not exceed 10 per cent. (10%) of the aggregate nominal amount of the issued share capital of the Company (excluding treasury shares) as at the date of the passing of this resolution and the approval pursuant to paragraph 5(2)(a) of this resolution shall be limited accordingly.”

By order of the Board
RENHENG Enterprise Holdings Limited
Liu Li
Chairman & Chief Executive Officer

Hong Kong, 29 April 2025

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. For the purpose of determining the right to attend and vote at the Annual General Meeting, the register of members of the Company will be closed from Friday, 20 June 2025 to Wednesday, 25 June 2025, both days inclusive, during which no transfer of Shares will be registered. In order to be entitled to attend and vote at the Annual General Meeting, unregistered holders of Shares should ensure that all transfers of Shares accompanied by the relevant share certificates and appropriate transfer forms must be lodged with the office of the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F Far East Finance Centre, 16 Harcourt Road, Hong Kong for registration not later than 4:30 p.m. on Thursday, 19 June 2025.
2. Any shareholder of the Company entitled to attend and vote at the annual general meeting convened by the above notice is entitled to appoint one or more than one proxies to attend and, subject to the provisions of the articles of association of the Company, to vote on his behalf. A proxy need not be a shareholder of the Company but must be present in person at the annual general meeting to represent the shareholder.
3. If the appointor is a corporation, the form of proxy must be under its common seal, or under the hand of an officer or attorney duly authorized on its behalf.
4. Where there are joint registered holders of any Share, any one of such persons may vote at the meeting, either personally or by proxy, in respect of such Shares as if he was solely entitled thereto; but if more than one of such joint holders be present at the meeting personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such Share shall alone be entitled to vote and will be accepted to the exclusion of other joint registered holders in respect hereof.
5. In order to be valid, a form of proxy, together with any power of attorney or other authority (if any) under which it is signed or a notarially certified copy of such power or authority must be deposited at the Company's Hong Kong branch share registrar, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road , Hong Kong, as soon as possible and in any event not less than 48 hours before the time appointed for holding the annual general meeting or any adjournment thereof. The completion and delivery of the form of proxy will not preclude a shareholder of the Company from attending in person and voting at the annual general meeting if he so wishes.
6. With respect to the resolution no. 5(1), approval is being sought from shareholders of the Company for a general mandate to issue Shares to be given to the Directors. The Directors wish to state that they have no immediate intention to issue any new Shares. Approval is being sought from the shareholders of the Company as a general mandate for the purpose of compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

As at the date of this notice, the executive Directors are Ms. Liu Li, Mr. Wen Yuan and Ms. Lew Lai Kuen and the independent non-executive Directors are Dr. Lam Lee G., Mr. Lam Chi Wing and Mr. Wu Wei.